To recover your password please fill in your email address
Please fill in below form to create an account with us
Title: Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling.
|
Trial Summary: |
The aim of this ASPiRATION and MoST substudy is to assess the clinical activity of combination of vemurafenib and cobimetinib in patients with newly diagnosed metastatic non-squamous small cell lung cancer (NSCLC) or other tumours harbouring BRAF V600 mutations. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with pathologically confirmed metastatic non-squamous NSCLC or other advanced cancers harbouring a BRAF V600 mutation. |
|
Registration ID: |
ACTRN12620000861954 |
|
Participation: |
National |
|
Status: |
In follow-up |
|
Activation Date: |
03/06/2021 |
|
Chairs: |
Dr Antony Mersiades and Dr Frank Lin |
|
Contact: |